主动脉内球囊反搏与Impella 5.5作为心脏移植桥接策略的比较
本研究基于美国器官共享数据库,比较2018年10月至2021年12月期间等待心脏移植期间使用IABP或Impella 5.5的患者的等待期和移植后结局。共识别2936例患者,其中2484例(85%)使用IABP,452例(15%)使用Impella 5.5。Impella组等待期死亡率显著更差且移植更少,但移植后2年生存率在完整队列和倾向性匹配队列中均相似。
要点
- Impella 5.5组患者病情更重,功能受损更明显、楔压更高、术前糖尿病和透析比例更高、呼吸机支持更多。
- Impella组等待期死亡率显著更差,移植频率更低(P < .001)。
- 移植后2年生存率在完整队列(90% vs 90%,P = .693)和倾向性匹配队列(88% vs 83%,P = .874)中均相似。
核心结论
- 使用Impella 5.5桥接的患者比IABP桥接患者病情更重且移植更少,但倾向性匹配队列中移植后结局相似。
- 这些桥接策略在心脏移植等待患者中的作用应随着未来分配系统变化而持续评估。
研究设计与样本
- 回顾性队列研究,利用美国器官共享数据库识别2018年10月至2021年12月期间列入心脏移植等待名单且等待期间任何时间接受IABP或Impella 5.5的患者。
- 共2936例患者,其中2484例(85%)接受IABP,452例(15%)接受Impella 5.5;创建倾向性匹配组。
- 采用Fine和Gray法进行竞争风险回归分析死亡率、移植和因病情从等待名单移除;移植后生存截尾于2年。
主要发现
- Impella 5.5组患者功能受损更重、楔压更高、术前糖尿病和透析比例更高、呼吸机支持更多(所有P < .05)。
- Impella组等待期死亡率显著更差且移植更少(P < .001)。
- 移植后2年生存率在完整队列中为90% vs 90%(P = .693),在倾向性匹配队列中为88% vs 83%(P = .874)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Temporary mechanical circulatory support is increasingly utilized as a bridge to heart transplantation. The Impella 5.5 (Abiomed) has achieved anecdotal success as a bridge since receiving US Food and Drug Administration approval. The purpose of the current study was to compare waitlist and posttransplant outcomes of patients bridged with intraaortic balloon pumps (IABPs) to those receiving Impella 5.5 therapy. METHODS: Patients listed for heart transplantation between October 2018 and December 2021 who received IABP or Impella 5.5 at any time during waitlist course were identified from the United Network for Organ Sharing database. Propensity-matched groups of recipients with each device were created. Competing-risks regression for mortality, transplantation, and removal from waitlist for illness was performed according to the method of Fine and Gray. Posttransplant survival was censored at 2 years. RESULTS: Overall, 2936 patients were identified, of whom 2484 (85%) were supported with IABP and 452 (15%) received Impella 5.5. Patients with Impella 5.5 support had more functional impairment, higher wedge pressures, higher rates of preoperative diabetes and dialysis, and more ventilator support (all P < .05). Waitlist mortality was significantly worsened in the Impella group and transplantation was less frequent (P < .001). However, survival at 2 years after transplant was similar in both complete (90% vs 90%, P = .693) and propensity-matched cohorts (88% vs 83%, P = .874). CONCLUSIONS: Patients bridged with Impella 5.5 were sicker than IABP-bridged patients and less frequently transplanted; however, posttransplant outcomes were similar in propensity-matched cohorts. The role of these bridging strategies in patients listed for heart transplantation should be continually assessed with future allocation system changes.
引用
- Iyengar A, Rekhtman D, Weingarten N, et al. Comparison of Intraaortic Balloon Pump and Impella 5.5 as Heart Transplant Bridging Strategies. Ann Thorac Surg. 2023. PMID: 37419173. doi:10.1016/j.athoracsur.2023.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。